Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Multi-Center, Open, 12-Week, Follow-up Safety and Efficacy Study of Serostim® in Subjects With Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome (HARS)

NCT01077960 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT01077960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01077960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Multi-Center, Open, 12-Week, Follow-up Safety and Efficacy Study of Serostim® in Subjects With Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome (HARS)
Lead sponsor
EMD Serono
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2005
Completion date
January 31, 2006
Enrollment
126 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus-associated adipose redistribution syndrome